IMPORTANT SAFETY INFORMATION
WARNING: HEPATOTOXICITY– Severe and sometimes fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue STIVARGA for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence. Continue reading below.
The Next Proven Step
Click here for more information.
Can be used to register the patient with REACH, which facilitates shipment of STIVARGA once insurance coverage is confirmed or the patient qualifies for the REACH assistance program